The results of this study demonstrated that for both AD models, when CT1812 analogues were administered at doses corresponding to 80% occupancy of the sigma-2 receptor, mice exhibited significant cognitive improvement compared to vehicle-treated mice [6]. This evidence concerns the gene TMEM97 and Alzheimer disease.